Clinical Trials - Physician

Clinical Trials - Physician

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
Olanzapine with or without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC) (A221602) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Open Label Study to Assess Olaparib as Treatment for Subjects with Different Homologous Recombination Deficiency (HRD) Tumor Status and With Platinum Sensitive Relapsed, High Grade Serous or High Grade Endometrioid Ovarian Cancer III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Open Label Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Axitinib in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naïve Cisplatin-Inelgible Urothelial Cancer (B9991027) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Open Label Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Axitinib in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naïve Cisplatin-Inelgible Urothelial Cancer (B9991027) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Pilot Study Evaluating Activity of the Combination of Anti-PD-1 Antibody with High Dose IL-2 in Metastatic Melanoma (MMP-MEL16-261) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields) in Combination with PD-1 Inhibitors or Docetaxel, for Second Line Treatment of Non-Small Cell Lung Cancer (EF-24) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Pivotal, Randomized, Open-Label Study of Tumor Treating Fields Concomitant with Gemcitabine and nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma (Panova-3) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Prospective Research Assessment in Multiple Myeloma: An observational Evaluation (PREAMBLE) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Protocol for a Research Database for Hematopoietic Cell Transplantation and Cellular Therapies (CIBMTR Research Database) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III NonSmall Cell Lung Cancer (COAST) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive, HER2 Neg, Breast Cancer (A011502) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Placebo-Controlled Study of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High Risk, HR+, HER2 Neg, Breast Cancer (S1207) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Adjuvant Concurrent Radiation and Chemotherapy vs Radiation Alone in Resected High Risk Malignant Salivary Gland Tumors (RTOG-1008) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Concurrent Chemotherapy and Pelvic Radiation with or without Adjuvant Chemotherapy in High Risk Patients with Early Stage Cervical Cancer Following Radical Hysterectomy (RTOG-0724) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus Deoxyribonucleic Acid (HN001)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in NonSmall Cell Lung Cancer (EA5142) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Olaparib vs Placebo as Adjuvant Treatment in Patients with BRCA 1, 2 Mutations and High Risk HER2 Neg Primary Breast Cancer Who Have Completed Definitive Local Treatment and Adj or NeoAdj Chemotherapy (B55) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer (A091302) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Tesetaxel Plus Capecitabine vs Capecitabine Alone in Patients with HER2 Neg, HR+, Locally Advanced or Metastatic Brast Cancer Previously Treated with a Taxane (ODO-TE-B301)(17009) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (16065) (UNITY205) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (A011401) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Adjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node Positive or High Risk Node Negative Triple Negative Invasive Breast Cancer (BR003) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Adjuvant Radiation vs Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy (GOG-0263) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (EA3132) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Erlotinib vs Placebo in Patients with Completely Resected EGFR Mutant NonSmall Cell Lung Cancer (A081105) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members